Back to Journals » Oncolytic Virotherapy

Oncolytic Virotherapy


Journal Articles:

- 50 records -

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect

Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ

Oncolytic Virotherapy 2017, 6:39-49

Published Date: 8 November 2017

Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity

Hotta Y, Kasuya H, Bustos I, Naoe Y, Ichinose T, Tanaka M, Kodera Y

Oncolytic Virotherapy 2017, 6:31-38

Published Date: 13 March 2017

Proinflammatory response induced by Newcastle disease virus in tumor and normal cells

Ginting TE, Suryatenggara J, Christian S, Mathew G

Oncolytic Virotherapy 2017, 6:21-30

Published Date: 3 March 2017

Editorial announcing PubMed indexing of Oncolytic Virotherapy

Farassati F

Oncolytic Virotherapy 2017, 6:19-20

Published Date: 15 February 2017

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma

Babiker HM, Riaz IB, Husnain M, Borad MJ

Oncolytic Virotherapy 2017, 6:11-18

Published Date: 9 February 2017

Novel oncolytic viral therapies in patients with thoracic malignancies

Ahmad Z, Kratzke RA

Oncolytic Virotherapy 2017, 6:1-9

Published Date: 21 December 2016

CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter

Bhatia S, O’Bryan SM, Rivera AA, Curiel DT, Mathis JM

Oncolytic Virotherapy 2016, 5:99-113

Published Date: 11 November 2016

Oncolytic virotherapy for pediatric malignancies: future prospects

Waters AM, Friedman GK, Ring EK, Beierle EA

Oncolytic Virotherapy 2016, 5:73-80

Published Date: 11 August 2016

Myxoma virus therapy of human embryonal rhabdomyosarcoma in a nude mouse model

Kinn VG, Hilgenberg VA, MacNeill AL

Oncolytic Virotherapy 2016, 5:59-71

Published Date: 8 August 2016

Oncolytic adenovirus-mediated therapy for prostate cancer

Sweeney K, Halldén G

Oncolytic Virotherapy 2016, 5:45-57

Published Date: 14 July 2016

Thyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapy

Guan M, Ma Y, Shah SR, Romano G

Oncolytic Virotherapy 2016, 5:35-43

Published Date: 21 June 2016

Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy

Al-Shammari AM, Rameez H, Al-Taee MF

Oncolytic Virotherapy 2016, 5:27-34

Published Date: 20 April 2016

High-throughput screening to enhance oncolytic virus immunotherapy

Allan KJ, Stojdl DF, Swift SL

Oncolytic Virotherapy 2016, 5:15-25

Published Date: 5 April 2016

Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances

Simpson GR, Relph K, Harrington K, Melcher A, Pandha H

Oncolytic Virotherapy 2016, 5:1-13

Published Date: 6 January 2016

Oncolytic virotherapy using herpes simplex virus: how far have we come?

Sokolowski NAS, Rizos H, Diefenbach RJ

Oncolytic Virotherapy 2015, 4:207-219

Published Date: 25 November 2015

Ultrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art

Nande R, Howard CM, Claudio PP

Oncolytic Virotherapy 2015, 4:193-205

Published Date: 25 November 2015

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy

Nakashima H, Nguyen T, Chiocca EA

Oncolytic Virotherapy 2015, 4:183-191

Published Date: 20 November 2015

Targeting tumor vasculature through oncolytic virotherapy: recent advances

Toro Bejarano M, Merchan JR

Oncolytic Virotherapy 2015, 4:169-181

Published Date: 11 November 2015

Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology

Ramírez M, García-Castro J, Melen GJ, González-Murillo A, Franco-Luzón L

Oncolytic Virotherapy 2015, 4:149-155

Published Date: 14 October 2015

Oncolytic Sendai virus-based virotherapy for cancer: recent advances

Saga K, Kaneda Y

Oncolytic Virotherapy 2015, 4:141-147

Published Date: 1 October 2015

Oncolytic virotherapy for human malignant mesothelioma: recent advances

Boisgerault N, Achard C, Delaunay T, Cellerin L, Tangy F, Grégoire M, Fonteneau JF

Oncolytic Virotherapy 2015, 4:133-140

Published Date: 10 September 2015

Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor

Sakr HI, Coleman DT, Cardelli JA, Mathis JM

Oncolytic Virotherapy 2015, 4:119-132

Published Date: 4 September 2015

Advances in the design and development of oncolytic measles viruses

Hutzen B, Raffel C, Studebaker AW

Oncolytic Virotherapy 2015, 4:109-118

Published Date: 27 August 2015

Oncolytic virotherapy for head and neck cancer: current research and future developments

Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM

Oncolytic Virotherapy 2015, 4:83-93

Published Date: 20 July 2015

Promising oncolytic agents for metastatic breast cancer treatment

Cody JJ, Hurst DR

Oncolytic Virotherapy 2015, 4:63-73

Published Date: 3 June 2015

Therapeutic potential of oncolytic Newcastle disease virus a critical review

Tayeb S, Zakay-Rones Z, Panet A

Oncolytic Virotherapy 2015, 4:49-62

Published Date: 27 March 2015

Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy

Whisenhunt Jr TR, Rajneesh KF, Hackney JR, Markert JM

Oncolytic Virotherapy 2015, 4:33-38

Published Date: 30 January 2015

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J

Oncolytic Virotherapy 2015, 4:25-31

Published Date: 28 January 2015

Immune cells: more than simple carriers for systemic delivery of oncolytic viruses

Eisenstein S, Chen SH, Pan PY

Oncolytic Virotherapy 2014, 3:83-91

Published Date: 6 November 2014

Reovirus in cancer therapy: an evidence-based review

Clements D, Helson E, Gujar SA, Lee PWK

Oncolytic Virotherapy 2014, 3:69-82

Published Date: 9 July 2014

Live attenuated measles virus vaccine therapy for locally established malignant glioblastoma tumor cells

Al-Shammari AM, Ismaeel FE, Salih SM, Yaseen NY

Oncolytic Virotherapy 2014, 3:57-68

Published Date: 3 May 2014

Applications of coxsackievirus A21 in oncology

Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F

Oncolytic Virotherapy 2014, 3:47-55

Published Date: 10 April 2014

Oncolytic viral therapy for pancreatic cancer: current research and future directions

Ady JW, Heffner J, Klein E, Fong Y

Oncolytic Virotherapy 2014, 3:35-46

Published Date: 17 February 2014

Oncolytic viral therapy: targeting cancer stem cells

Smith TT, Roth JC, Friedman GK, Gillespie GY

Oncolytic Virotherapy 2014, 3:21-33

Published Date: 7 February 2014

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs

Braidwood L, Graham SV, Graham A, Conner J

Oncolytic Virotherapy 2013, 2:57-74

Published Date: 6 December 2013

Cell carriers for oncolytic viruses: current challenges and future directions

Roy DG, Bell JC

Oncolytic Virotherapy 2013, 2:47-56

Published Date: 10 October 2013

Oncolytic virus therapy for cancer

Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL

Oncolytic Virotherapy 2013, 2:31-46

Published Date: 24 September 2013

Oncolytic virotherapy: the questions and the promise

Aurelian L

Oncolytic Virotherapy 2013, 2:19-29

Published Date: 4 June 2013

Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma

Doty RA, Liu J, McFadden G, Roy EJ, MacNeill AL

Oncolytic Virotherapy 2013, 2:1-17

Published Date: 14 January 2013

Oncolytic virotherapy for ovarian cancer

Li SD, Tong J, Rahman MM, Shepherd TG, McFadden G

Oncolytic Virotherapy 2012, 1:1-21

Published Date: 23 August 2012